Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $53
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $48 to $53.
Read original at benzingaStocks · News reference
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $46
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $40 to $46.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 6:52 PM
- Checked
- Aug 7, 2026, 6:52 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.15 percent. This is a 10.59 percent decrease over losses of $(0.85) per share
Read original at benzingaWells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72
Read original at benzinga